Director/PDMR Shareholding

RNS Number : 6310P

e-Therapeutics plc

26 October 2012

 

e-Therapeutics plc("e-Therapeutics" or "the Company")

Award of options under the e-Therapeutics Long-Term Incentive Plan ("LTIP")

e-Therapeutics (AIM: ETX), the drug discovery and development company, announces that on 26 October 2012 options to acquire at par value new ordinary shares of 0.1p each in the Company were awarded to Directors under the terms of the Company's LTIP as detailed below:

Director	Options awarded	Total shares under option after this grant (% of current issued share capital)	Ordinary shares held (% of current issued share capital)
Malcolm Young	200,000	684,390 (0.5%)	21,023,630 (15.2%)*
Steve Self	200,000	1,268,453 (0.92%)	253,577 (0.2%)
Daniel Elger	200,000	862,690 (0.62%)	15,000 (0.01%)

* including connected persons and shares held indirectly

In addition, options over a total of 341,154 shares were awarded to other employees.

The options are subject to the following conditions:

-     they will be exercisable between the third anniversary of grant and six months thereafter but only if the Company's shares reach an average closing price (measured on a rolling 20-day basis) of 100 pence on a trading day within that period.

-     they may be exercised sooner in the event of a change of control, but only if the price offered by the party acquiring control of the Company is at least 67 pence per share.

As at the date of this announcement, and including the above, there are options and warrants outstanding over 6,966,667 ordinary shares in the Company, amounting to approximately 5.0% of the current issued share capital.

Contacts

e-Therapeutics plc Tel: [phone]

Daniel Elger, CFO

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited Tel: [phone]

Fred Walsh / Hannah Woodley / Grishma Patel

www.panmure.com 

College Hill Tel: [phone]

Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill

Email: [e-mail]

 

END

 

 

RDSLIFFAISLRFIF